Last reviewed · How we verify
Hepatitis B Vaccine
The Hepatitis B vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen, providing protection against hepatitis B virus infection.
The Hepatitis B vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen, providing protection against hepatitis B virus infection. Used for Prevention of hepatitis B virus infection in infants, children, and adults.
At a glance
| Generic name | Hepatitis B Vaccine |
|---|---|
| Also known as | HB-Vax-II, Hep B vaccine, Euvax B (Sonafi), Engerix-B, HBVAXPRO |
| Sponsor | Murdoch Childrens Research Institute |
| Drug class | vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains hepatitis B surface antigen (HBsAg), typically produced via recombinant DNA technology, which triggers both humoral and cellular immune responses. This leads to the production of protective antibodies (anti-HBs) and memory B cells that recognize and neutralize the virus upon exposure, preventing infection and chronic disease.
Approved indications
- Prevention of hepatitis B virus infection in infants, children, and adults
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fatigue
- Headache
Key clinical trials
- Evaluation of Patients With Liver Disease
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
- Fungal Infection Susceptibility
- Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
- Evaluation of Patient Care Support for Cirrhosis and/or Liver Transplants
- Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV (PHASE2)
- The Mechanistic Biology of Primary Immunodeficiency Disorders
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hepatitis B Vaccine CI brief — competitive landscape report
- Hepatitis B Vaccine updates RSS · CI watch RSS
- Murdoch Childrens Research Institute portfolio CI